Bio View (XTAE:BIOV) Debt-to-Equity : 0.13 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Bio View Debt-to-Equity?

Bio View's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪1.56 Mil. Bio View's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₪1.95 Mil. Bio View's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₪27.31 Mil. Bio View's debt to equity for the quarter that ended in Dec. 2023 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bio View's Debt-to-Equity or its related term are showing as below:

XTAE:BIOV' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.13 Max: 0.17
Current: 0.13

During the past 13 years, the highest Debt-to-Equity Ratio of Bio View was 0.17. The lowest was 0.06. And the median was 0.13.

XTAE:BIOV's Debt-to-Equity is ranked better than
63.64% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 0.215 vs XTAE:BIOV: 0.13

Bio View Debt-to-Equity Historical Data

The historical data trend for Bio View's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View Debt-to-Equity Chart

Bio View Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.06

0.17

0.14

0.13

Bio View Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.15	0.15	0.14	0.14	0.13

Competitive Comparison of Bio View's Debt-to-Equity

For the Medical Devices subindustry, Bio View's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio View's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bio View's Debt-to-Equity falls into.

Bio View Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bio View's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.555	+	1.951)	/	27.305
	=	0.13

Bio View's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.555	+	1.951)	/	27.305
	=	0.13

Bio View (XTAE:BIOV) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bio View Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bio View's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio View (XTAE:BIOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Pekeris Street, Rehovot, ISR, 7670203

Website

http://www.bioview.co.il

Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View (XTAE:BIOV) Headlines

No Headlines